Stephanie Vertrees
Neurology · Austin, TXNPI 1194941211
Payments from drug & device makers
Across 477 payments — averaging $250.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$39K
- AbbVie$37K
- Lilly USA, LLC$26K
- Amgen$10K
- Lundbeck LLC$5K
- Teva Pharmaceuticals USA, Inc.$483
- plus $1K from 16 others
What the payments were for
- Consulting fees$13,11011%
- Speaking & faculty fees$94,80979%
- Travel & lodging$2,8232%
- Food & beverage$8,4737%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 85 | $39,062 |
| AbbVie(2 entities) | 157 | $37,007 |
| Lilly USA, LLC | 79 | $26,447 |
| Amgen | 38 | $10,335 |
| Lundbeck LLC | 21 | $4,590 |
| Teva Pharmaceuticals USA, Inc. | 23 | $483 |
| Biohaven Pharmaceutical Holding Company Ltd. | 35 | $381 |
| Biohaven Pharmaceuticals, Inc. | 10 | $188 |
| Axsome Therapeutics, Inc. | 4 | $157 |
| Novartis | 5 | $115 |
| Tonix Medicines, Inc. | 2 | $114 |
| Eli Lilly | 1 | $87 |
| Impel Pharmaceuticals LLC | 4 | $71 |
| Upsher-smith Laboratories LLC | 4 | $70 |
| Ipsen Biopharmaceuticals, Inc | 2 | $47 |
| Revance Therapeutics, Inc. | 1 | $35 |
| Merz Pharmaceuticals, LLC | 1 | $28 |
| Collegium Pharmaceutical, Inc. | 1 | $25 |
| Impel Pharmaceuticals Inc. | 1 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Abbott | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$119,326 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 23 | $32,619 |
| Sumatriptan Succinate | 15 | $310 |
| Prochlorperazine Maleate | 19 | $199 |
| Gabapentin | 11 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $39,062 | $32,61923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 neurology providers in Texas.
Other neurology in Austin
- Esther MelamedAustin$593K
- Sami AboumatarAustin$593K
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.